News
AstraZeneca Readies for Tagrisso Competition in First-Line Advanced Lung Cancer as Q2 Revenues Surge
The impact of Tagrisso plus chemo on overall survival in a Phase III trial has boosted the firms' confidence to parry competitors.
AstraZeneca (LSE: AZN) posted a robust second-quarter 2025 performance, lifted by record growth in its US business and solid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback